“Our goal is to help you propel scientific progress.”
As a startup, Illumina aspired to transform human health. Its initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go.
While the rate of progress is accelerating exponentially, it is only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate?
What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire us to push the boundaries of its imagination.
Today, the company is a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, it enables the customers to read and understand genetic variations. It strives to make its solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.
Future of Human Health
Illumina FastTrack Sequencing : This has been providing whole-genome sequencing services for years. FastTrack Services excels in delivering a fast sample-to-data whole-genome solution to customers, and guarantees delivery of the highest quality data through automated and traceable processes to certify data integrity throughout. The lab offers years of experience with proven Illumina sequencing technology, and production continues to grow year over year. Additionally, FastTrack Sequencing Services provides exceptional customer support, offering customers personalized attention as their project progresses from start to finish. Since adding whole-genome sequencing service capabilities to Illumina FastTrack Services in 2009, the lab has completed projects for a broad range of areas, including cancer and complex disease. Whole-genome sequencing services enable customers specializing in these fields to cost-effectively identify novel variants, empowering disease association studies like never before.
Illumina FastTrack Microarray : This works collaboratively to achieve research objectives. Since 2001, it has consistently provided on-time, reliable microarray services, including genotyping and methylation array services, to academic and pharmaceutical customers.
Its in-house expert molecular geneticists use Illumina’s cutting-edge array technologies. Enjoy the same competitive edge, its Illumina instrument owners have – conduct whole-genome association studies, linkage analysis, and fine mapping studies in a timely fashion at a reasonable cost.
Illumina FastTrack Microarray Services offers years of experience providing genotyping services with Illumina’s proven array technology. The lab has genotyped over 1 million samples across 600 projects.
Illumina offers certification programs : This is to help support the needs of service laboratories and the customers they serve. Its Propel Certification Program validates and benefits academic, government, and non-profit core labs, as well as commercial service labs.
Illumina has evolved the existing CSPro program into a more powerful one – the Illumina Propel Certification Program. Illumina will be discontinuing the CSPro program and replacing it in its entirety with the Propel Certification Program.
The Illumina Propel Certification Program is an evolution of the Illumina Certified Service Provider (CSPro) program launched in Upon demonstrating yearly competency with select Illumina products through a carefully designed, standardized process, participating core and commercial service laboratories will gain access to a powerful set of benefits designed to accelerate, differentiate, and propel their lab forward.
Meet the Key Executive
Francis deSouza, President & CEO: Francis deSouza was appointed President & CEO of Illumina in 2016 and is responsible for directing all aspects of company strategy, planning, and operations. He initially joined the company as President in 2013, and led Illumina’s business units and core functions responsible for envisioning, developing and producing the company’s products. Previously, deSouza served as President of Products and Services at Symantec Corporation, where he was responsible for driving the vision for the company’s market-leading portfolio and served in a variety of executive roles. He joined Symantec through the acquisition of IMlogic, where he was co-founder and CEO.
Prior to joining IMlogic, deSouza was co-founder and CEO of Flash Communications, a provider of corporate instant messaging that was acquired by Microsoft. Following the acquisition, he joined Microsoft and led the team responsible for the development of the company’s enterprise real-time collaboration offerings. Currently, he is Chairman of the Board for MedHelp, the world’s largest online health community. Francis deSouza received a B.S. and M.S. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.
“We’ve been advancing industry-leading solutions that offer flexible content and scalable multiplexing for diverse DNA, RNA, and epigenetic applications.”
Benchmark Electronics will develop Qualcomm’s biometric patches to monitor vital signs and track patients